AstraZeneca buys CDK9 portfolio

The company purchased assets from Germany-based Probiodrug.

January 6, 2014

6:57 pm

AstraZeneca has purchased the CDK9 portfolio of Germany-based Probiodrug AG. The Halle, Germany, biotech announced the deal Thursday, but did not disclose the price tag.

The agreement means AstraZeneca will now own the lead drug and back-up compounds associated with the molecule, which has an impact on genetic transcription connected to inflammation, a condition which is associated with cancer and inflammatory diseases.

From Our Partners

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

Partner Content

HUB services, patient engagement, and specialty pharmacy: One patient support ecosystem with three core components

The evolution of patient needs and rising consumer expectations are shaping a new era in healthcare — one that calls for a paradigm shift in the pharmaceutical industry's approach to patient support.

Omnichannel activation without omniburden

Partner Content

Omnichannel activation without omniburden

Explore solutions for practically implementing omnichannel approaches into your go-to-market activation.

Taking a patient-centric approach to privacy

Partner Content

Taking a patient-centric approach to privacy

This podcast will explore ways to deliver tailored content that activates, educates and empowers patients while prioritizing privacy and consent.

Living brands: How to build brands in the age of omnichannel

Partner Content

Living brands: How to build brands in the age of omnichannel

This podcast looks at how to leverage advancements in data, technology, AI and content development in order to become a Living Brand.